Harbin Pharmaceutical Group Co

Harbin Pharmaceutical Group Co Gross Margin

The Gross Margin of Harbin Pharmaceutical Group Co (600664.SS) as of Oct 21, 2026 is 25.98 %. In the previous year, Gross Margin was 27.95 % — a change of -7.02% (lower).

Gross Margin

25.98 %

YoY

-7.02%

Last updated:

Gross Margin of Harbin Pharmaceutical Group Co is 2025 25.98 % . Gross Margin of Harbin Pharmaceutical Group Co was 2024 27.95 % . It decreases by -7.02% lower compared to the previous year.

Harbin Pharmaceutical Group Co's gross margin stands at 26.0%, up from 23.2% several years earlier.

The Harbin Pharmaceutical Group Co Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
26.78 CNY
Jan 1, 2019
23.67 CNY
Jan 1, 2020
20.81 CNY
Jan 1, 2021
23.24 CNY
Jan 1, 2022
24.35 CNY
Jan 1, 2023
25.97 CNY
Jan 1, 2024
27.95 CNY
Jan 1, 2025
25.98 CNY
The Harbin Pharmaceutical Group Co Gross Margin history
YEARGross MarginYoY
25.98 %-7.02%
27.95 %+7.63%
25.97 %+6.63%
24.35 %+4.76%
23.24 %+11.69%
20.81 %-12.08%
23.67 %-11.61%
26.78 %+3.45%
25.89 %-1.21%
26.20 %+7.21%
24.44 %-9.68%
27.06 %+9,429.72%
0.28 %-10.61%
0.32 %+34.79%
0.24 %-20.99%
0.30 %-6.76%
0.32 %-0.04%
0.32 %-2.37%
0.33 %-5.17%
0.35 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Harbin Pharmaceutical Group Co Stock analysis

What does Harbin Pharmaceutical Group Co do? Harbin Pharmaceutical Group Co., Ltd. generates revenue by engaging in the research, development, manufacture, wholesale, and retail of pharmaceutical products. The firm focuses on innovative research and development in high-tech fields such as antibiotics, modern Chinese medicine, and biopharmaceuticals. These activities support its main business sectors, which include antibiotics, over-the-counter drugs and health products, traditional and modern Chinese medicine, biomedicine, and pharmaceutical commerce. The company produces a wide range of items, including calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, alprostadil injection, pediatric paracetamol Huangnamin granules, lacidipine tablets, hydrochloric acid for injection Cefotiam, ibuprofen granules, and Xingaizhonggai high calcium tablets. The business is structured around these diverse product lines, serving the needs of the pharmaceutical commerce sector and consumers requiring specific medical treatments. By covering the entire value chain from research and development to retail, the company monetizes its expertise in high-tech fields. The products listed, such as Shuanghuanglian oral solution and amoxicillin capsules, represent the tangible outputs of its manufacturing and wholesale operations, which are central to its financial model. Harbin Pharmaceutical Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Harbin Pharmaceutical Group Co stock

Gross Margin of Harbin Pharmaceutical Group Co is 25.98 % in 2025.

Gross Margin of Harbin Pharmaceutical Group Co changed from 27.95 % to 25.98 %, representing a -7.02% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Harbin Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Harbin Pharmaceutical Group Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Harbin Pharmaceutical Group Co

All Key Metrics — Harbin Pharmaceutical Group Co